A Phase 1 interventional study of Cetirizine and Cetirizine in Allergy, sponsored by McNeil AB. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-10.
Sponsored by McNeil AB (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Hypersensitivity with a site in Canada — 8 open to participants now, 12 under way, 1 of them phase 3. Hypersensitivity · Canada.
Among the 86 studies in Hypersensitivity with a site in Canada, this one is the 51st largest by enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2011, is one of 10 in phase 1, and was the 29th registered.
1,058 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.
Browse Hypersensitivity studies →8 of the 86 studies in Hypersensitivity with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 37 wk–42 wk
Dr. George Luciuk · Sites in Canada
Ages 12+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Cogent Biosciences, Inc. · Sites in Canada, United States, Australia and 11 more countries
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 30 · Phase 3 18 · Phase 4 4
First in 2004; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 73 across 691 interventional studies indexed under Hypersensitivity.
Median enrollment 64 across the 71 interventional studies, 107 across the 15 observational. Of the 65 that completed or were terminated, 18 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under McNeil AB, one of the names counted as Johnson & Johnson. Under that name alone:
McNeil AB is the lead sponsor of 42 studies on the registry; 1 is open to participants now.
Johnson & Johnson has 4 studies filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypersensitivity with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT06189742Dr. Anne EllisTezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) | 2026-12 |
| NCT07038746Dr. George LuciukEffects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges | 2026-12 |
| NCT07917312Philippe BéginEvaluating Sucrose and Cold Oral Interventions for the Treatment of Oral Pruritus During Allergy Procedures. | 2027-06-01 |
| NCT05011071University of CalgaryThe Alberta BLOOM Premature Child Study | 2027-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 86 studies in Hypersensitivity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess bioequivalence between two products used for treatment of allergy.
This study is designed to evaluate if a test formulation of cetirizine 10 mg orodispersible tablet (ODT) taken with and without water is bioequivalent to a marketed reference formulation of cetirizine 10 mg tablet (Benadryl One A Day, McNeil Products Ltd, UK) taken with water. This study will also evaluate the tolerability of test and reference formulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
Drug: Cetirizine
Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
Drug: Cetirizine
Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
Drug: Cetirizine
A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
Also known as: Not yet marketed
A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
Also known as: Benadryl One A Day 10 mg Film-Coated Tablet
Maximum Observed Plasma Concentration
Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)
Time frame: During 32 hours post-dose
Bioavailability [AUC(0-t)]
Bioavailability \[AUC(0-t)\] is a measure of how much of the drug reaches the person's bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour \* nanograms (ng) per milliliter (mL).
Time frame: During 32 hours post-dose
Bioavailability Extrapolated to Infinity [AUC (0-∞)]
Bioavailability Extrapolated to Infinity \[AUC (0-∞)\] is a calculated measure of how much of the drug will ever reach the person's bloodstream for the body to use. AUC (0-∞) stands for the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (forever). It is obtained from calculating AUC (0-t) plus AUC (t-∞).
Time frame: 32 hours post-dose
Time of Maximum Concentration
The time at which maximum concentration is reached (Tmax)
Time frame: During 32 hours post-dose
Terminal Elimination Rate Constant
The Terminal Elimination Rate Constant (Lamda z) is the time required to eliminate half the administered dose
Time frame: During 32 hours post-dose
Terminal Phase Plasma Half-Life
Terminal phase plasma half-life (t ½) is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, rather than the time required to eliminate half the administered dose.
Time frame: During 32 hours post-dose
Area under the Curve to the Tmax of the Reference Products
Area under the plasma concentration versus time curve to the time of the maximum concentration of the reference products (AUCReftmax)
Time frame: During 32 hours post-dose
Relative percentage of AUCT with respect to AUC∞ (AUCT/∞)
AUCT is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration. AUC∞ is the area under the plasma concentration versus time curve from start of drug administration until extrapolated infinite time. AUCT/ AUC∞ is an inversed measure of how large the extrapolated area under the curve is.
Time frame: During 32 hours post-dose
Mean Residence Time
The average amount of time a particle (e.g., a drug substance molecule) remains in a compartment or system.
Time frame: During 32 hours post-dose
The record gives a start of Feb 2011, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine